Amneal Announces Solid Third Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Amneal Pharmaceuticals (AMRX) Reports In-Line Q3 EPS, Revenues Miss
November 7, 2018 6:58 AM ESTAmneal Pharmaceuticals (NYSE: AMRX) reported Q3 EPS of $0.28, in-line with the analyst estimate of $0.28. Revenue for the quarter came in at $476.46 million versus the consensus estimate of $485.97 million.
"The third quarter was defined by solid financial performance and strategic accomplishments as we advanced the integration of Impax and Amneal, completed two strategic partnerships that strengthen our portfolio and launched 11 new generic products," said Rob Stewart, President and CEO of Amneal. "We delivered revenue of $476 million and adjusted... More
